通过计算设计可提高 CAR T 细胞抗肿瘤功效的蛋白质结合剂

IF 26.8 1区医学 Q1 ENGINEERING, BIOMEDICAL Nature Biomedical Engineering Pub Date : 2024-10-24 DOI:10.1038/s41551-024-01263-x

{"title":"通过计算设计可提高 CAR T 细胞抗肿瘤功效的蛋白质结合剂","authors":"","doi":"10.1038/s41551-024-01263-x","DOIUrl":null,"url":null,"abstract":"We computationally designed protein binders for chimeric antigen receptor (CAR) constructs to target the glioblastoma-associated antigens EGFR and CD276. Compared with standard CAR T cells, CAR T cells with the de novo-designed binders showed enhanced proliferation, cytokine release and resistance to exhaustion, as well as superior antitumour effects in vitro and in vivo.","PeriodicalId":19063,"journal":{"name":"Nature Biomedical Engineering","volume":null,"pages":null},"PeriodicalIF":26.8000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Computational design of protein binders that boost the antitumour efficacy of CAR T cells\",\"authors\":\"\",\"doi\":\"10.1038/s41551-024-01263-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We computationally designed protein binders for chimeric antigen receptor (CAR) constructs to target the glioblastoma-associated antigens EGFR and CD276. Compared with standard CAR T cells, CAR T cells with the de novo-designed binders showed enhanced proliferation, cytokine release and resistance to exhaustion, as well as superior antitumour effects in vitro and in vivo.\",\"PeriodicalId\":19063,\"journal\":{\"name\":\"Nature Biomedical Engineering\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":26.8000,\"publicationDate\":\"2024-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Biomedical Engineering\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1038/s41551-024-01263-x\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Biomedical Engineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1038/s41551-024-01263-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

摘要

我们通过计算设计了嵌合抗原受体（CAR）构建体的蛋白结合体，以靶向胶质母细胞瘤相关抗原表皮生长因子受体（EGFR）和CD276。与标准的CAR T细胞相比，带有全新设计的结合剂的CAR T细胞在体外和体内的增殖、细胞因子释放和抗衰竭能力都有所增强，抗肿瘤效果也更出色。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Computational design of protein binders that boost the antitumour efficacy of CAR T cells

We computationally designed protein binders for chimeric antigen receptor (CAR) constructs to target the glioblastoma-associated antigens EGFR and CD276. Compared with standard CAR T cells, CAR T cells with the de novo-designed binders showed enhanced proliferation, cytokine release and resistance to exhaustion, as well as superior antitumour effects in vitro and in vivo.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Biomedical Engineering Medicine-Medicine (miscellaneous)

CiteScore

45.30

自引率

1.10%

发文量

138

期刊介绍： Nature Biomedical Engineering is an online-only monthly journal that was launched in January 2017. It aims to publish original research, reviews, and commentary focusing on applied biomedicine and health technology. The journal targets a diverse audience, including life scientists who are involved in developing experimental or computational systems and methods to enhance our understanding of human physiology. It also covers biomedical researchers and engineers who are engaged in designing or optimizing therapies, assays, devices, or procedures for diagnosing or treating diseases. Additionally, clinicians, who make use of research outputs to evaluate patient health or administer therapy in various clinical settings and healthcare contexts, are also part of the target audience.